key: cord-0959695-7uz4jtk3 authors: Etemadifar, M.; Nouri, H.; Pitzalis, M.; Idda, M. L.; Salari, M.; Baratian, M.; Mahdavi, S.; Abhari, A. P.; Sedaghat, N. title: Multiple sclerosis disease-modifying therapies and COVID-19 vaccines: A practical review and meta-analysis date: 2022-02-13 journal: nan DOI: 10.1101/2022.02.12.22270883 sha: 841704a9591befe7480fa66e361a50e9a7a6dabe doc_id: 959695 cord_uid: 7uz4jtk3 Importance: An evidence-based appraisal of the COVID-19 vaccination policies among people with multiple sclerosis (pwMS) with respect to disease-modifying therapies (DMT) is important for our understandings and their further management. Objective: To synthesize the available evidence concerning the effect of DMTs on COVID-19 vaccination immunogenicity and effectiveness. Data Sources: We searched MEDLINE, Scopus, Web of Science, MedRxiv, and Google Scholar from January 2021 until January 2022. Study Selection: The exclusion criteria included: not a primary investigation; retracted/withdrawn; no eligible participants - people with no history/evidence of previous COVID-19 and corticosteroid administration within two months of vaccination; no eligible exposures - all nine DMT classes; and no eligible comparators - DMT-unexposed at the time of vaccination. Data Extraction and Synthesis: Entries were assessed independently by two reviewers for eligibility and quality. Dichotomized data was extracted by two reviewers in accordance with Cochrane guidelines, and were pooled using either Peto fixed-effects or Inverse-variance random-effects methods. Main Outcomes and Measures: Main outcomes were i) B-cell response, measured by seroconversion odds ratio (OR); ii) T-cell response, measured by interferon-gamma release response OR, and CD4+/CD8+ activation-induced marker+ OR. Further outcomes including immunity waning speed and breakthrough COVID-19 incidence/severity were synthesized narratively. Results: Data from 28 studies (5,025 pwMS and 1,635 healthy participants) after COVID-19 vaccination suggests mildly-lower B-cell responses in teriflunomide- and alemtuzumab-treated, extensively-lower B-cell responses in sphingosine-1-phosphate receptor modulator (S1PRM)- and anti-CD20 (aCD20)-treated, and lower T-cell responses in interferon-, S1PRM-, alemtuzumab- and cladribine-treated pwMS. Every ten-week increase in aCD20-to-vaccine period is associated with a 1.94-time (95%CI: 1.57, 2.41, P<0.00001) increase in odds of seroconversion. B-cell-depleting therapies seem to accelerate post-vaccination humoral waning, and booster immunogenicity is predictable with the same factors affecting the priming vaccination. Furthermore, comparatively-increased breakthrough COVID-19 incidence and severity is being observed only among S1PRM- and anti-CD20-treated pwMS - i.e., among the pwMS with extensively-blunted B-cell response, despite adequate T-cell responses in the aCD20-treated. To date, pwMS on only-T-cell-blunting DMTs have not shown increased susceptibility to breakthrough COVID-19. Conclusion and Relevance: The implemented vaccination strategy to date has been effective for pwMS on all DMTs other than S1PRM and aCD20. As B-cell immunity seems to be a more important predictor of vaccine effectiveness than T-cell immunity, optimization of humoral immunogenicity and ensuring its durability among pwMS on DMTs are the necessities of an effective COVID-19 vaccination policy. One study with limited sample size utilizing AIM assays 23 (very low-certainty evidence), suggested 125 decreased odds of positive response neither in CD4+ (OR not measurable) nor CD8+ (OR [95%CI]: 0.62 126 [0.04, 9 .00], P=0.72) T-cells. Furthermore, it is worth mentioning that adequate interferon-gamma release 127 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 DMF-treated pwMS after SARS-CoV-2 infection, suggesting adequate T-cell response 24 . 140 Inadequate number of studies with considerable heterogeneity (very-low-certainty evidence) suggest 142 P=0.09). Nevertheless, considering that none of the TERI-treated pwMS in any of the studies 16,18,22,25-28 147 remained seronegative after mRNA vaccination, the suggested blunt caused by TERI may not be 148 generalizable to the mRNA-vaccinated pwMS. Furthermore, lower antibody concentrations compared to 149 UX people were observed in pwMS on TERI homogenously in all studies regardless of the used vaccine, 150 but reached statistical significance only in one 28 . TERI's mechanism of action -which involves inhibition 151 of rapidly-dividing cells, including activated B-cells -may explain this observation. 152 Furthermore, no evidence was found regarding the T-cell responses in these pwMS following vaccination; 153 Assessing the vaccine-induced T-cell responses in TERI-treated pwMS is therefore encouraged. 154 High-certainty evidence confirms significantly lower odds of post-vaccination seroconversion in pwMS on 156 S1PRM compared with UX people (OR [95%CI]: 0.04 [0.03, 0.06], P<0.00001) (Supplementary Figure 5) . 157 All included studies 16, 17, [19] [20] [21] [22] [25] [26] [27] [28] [29] [30] [31] found significantly lower concentrations of antibodies following 158 vaccination in these pwMS compared to UX people. Studies with heterogenous effect measures 159 (moderate-certainty evidence) indicate that with the current vaccination strategy, pwMS on S1PRM are 25 160 times (95%CI: 16.66, 33.33) less likely to show anti-S1, and 8.33 times (95%CI: 3.70, 20) less likely to 161 show anti-S seroconversion following COVID-19 vaccination (Chi 2 =7.24, P<0.01). Paradoxical to the 162 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2022 healthy population, low-certainty evidence -due to limited count of inactivated vaccine studies -suggests 163 that among the pwMS on S1PRM, odds of anti-S1 seroconversion is higher with inactivated vaccines 164 compared to mRNA and AV vaccines (Chi 2 =11.97, P<0.001). Although theoretically reasonable 32 , head-165 to-head mRNA-AV 29 and mRNA-inactivated 22 immunogenicity comparisons in S1PRM-treated pwMS 166 have suggested the opposite. Hence, the need for more replication of inactivated/mRNA/AV comparisons 167 is clearly sensed for pwMS on S1PRM. 168 Furthermore, interferon-gamma release assays in two studies 20,26 (low-certainty evidence) suggested 169 decreased odds of positive T-cell response in pwMS on S1PRM ( Additionally, among the pwMS on S1PRM who failed to seroconvert following priming vaccination, one 175 study showed that administration of booster doses increased anti-S1 antibody concentrations, but 176 promoted seroconversion only in 2/29 (7%) 33 . 177 The trafficking inhibition of lymphocytes, their restriction to lymphatics, and hence, the peripheral 178 lymphopenia seen in pwMS on S1PRM explains the lower T-cell reactivity observed in peripheral blood 179 samples -not to mention S1PRM's documented inhibitive effect on T-cell activation 34 . The former reason 180 may also explain the blunted humoral responses, as the one-way flow of lymph from peripheral to central 181 areas restricts trafficking of lymphocytes to peripheral areas, inhibiting proper exposure of lymph-trapped 182 lymphocytes to immunizing materials of the vaccines which are administered peripherally/locally. As 183 systemic SARS-CoV-2 infection mounts adequate immunization among pwMS on S1PRM 32, 35 , it can be 184 hypothesized that immunogenicity in these people is subject to wider (e.g., systemic instead of 185 local/peripheral) exposure to immunogens. When the lymphocytes' ability to reach the immunogens is 186 inhibited, the immunogens should reach the lymphocytes themselves or immunization will not develop. 187 Compared to UX people, low-certainty evidence did not confirm lower odds of anti-S1 seroconversion 189 among pwMS on NTZ following vaccination (OR [95%CI]: 0.53 [0.24, 1.18]) (Supplementary Figure 7) . All 190 pwMS on NTZ in seven studies -including the only two studies using anti-S assays with extractable data 191 23,36 -seroconverted following vaccination 16, 17, 23, 25, 26, 28, 36 . Although relative effect was measurable in only 192 two of them which contained seronegative UX people 26, 28 . Unlike all the other studies, pwMS on NTZ in 193 one study 28 showed significantly lower post-vaccination antibodies compared to UX people. gamma release 17 and AIM 23 assays (very low-certainty evidence) did not suggest blunted post-195 vaccination T-cell responses in pwMS on NTZ compared to UX people. 196 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; are inhibited, the preserved presence of lymphocytes in blood flow -which, unlike the lymph flow, can be 200 from central to peripheral areas as well -may be the reason NTZ does not blunt vaccination-induced 201 immunization as much as S1PRM. Compared to its effect on the T-cell lineage, CLAD's effect on the B-cells is more extensive but less 213 durable [37] [38] [39] [40] . As interpreted, this has been translated into observation of proper humoral despite blunted 214 cellular immunization following COVID-19 vaccination among pwMS on CLAD. Furthermore, the time 215 since the last CLAD dose theoretically affects humoral responses; This was suggested especially by 216 Achiron et al. study 26 but did not reach statistical significance, and was not confirmed by other studies 217 25, 28, 41 ; It seems the implemented guidelines 1-4 have suggested an adequate amount of post-CLAD 218 vaccination delay to prevent blunted humoral responses, and therefore, made the probable effect 219 unmeasurable. Additionally, although CLAD depletes the memory B-cells 42 , a preliminary study 220 suggested its subsequent doses will not alter pre-existing humoral memory 43 ; Still, there is limited 221 evidence that the longevity of COVID-19 vaccine-induced humoral responses is lower in pwMS on CLAD 222 26 . Replicative studies measuring the immunity waning speed in these pwMS after COVID-19 vaccination 223 are, therefore, required to determine whether they require personalized booster schedules. 224 Pooled very-low-certainty evidence (Supplementary Figure 9 ) suggests lower odds of anti-S1 226 seroconversion among pwMS on ALEM compared to UX people (OR [95%CI]: 0.32 [0.10, 0.96], P=0.04). 227 One study assessed anti-S seroconversion, but its data could not be extracted 30 Quantitative analyses in most studies 17, 20, 23, 29, [45] [46] [47] [48] were in line with the dichotomized evidence. Multiplex 254 polymerase chain reaction assay in one study 49 indicated positive adaptive T-cell responses among 100% 255 of seronegative pwMS on aCD20 following vaccination. 256 Furthermore, the preliminary evidence indicates significant decline in seropositivity rates of pwMS on 257 aCD20 six months after their second dose 50,51 . Homologous mRNA boosters in pwMS on aCD20 258 promoted T-cell responses 52 , while humoral responses were still heavily dependent on the serostatus 259 following the priming regimen, and B-cell dynamics at the time of booster administration 33,51-53 ; In other 260 words, the booster doses did not promote humoral immunization in pwMS on aCD20 who did not 261 seroconvert following priming vaccination, unless their B-cells were reconstituted. Studies among people 262 on aCD20 with diseases other than MS 54,55 support the same conclusion. 263 Similar to pwMS on other DMTs, the COVID-19 vaccines' immunogenicity among pwMS on aCD20 could 264 be considered a translation of the previously-determined B-and T-cell dynamics in them 40, 56 , based on 265 which the current guidelines recommended a 12-to-36-week window between aCD20 infusion and 266 COVID-19 vaccination 1-4 . However, the presented evidence suggests that the mentioned interval, 267 although increases the odds, will not be adequate to reverse the humoral blunts in pwMS on aCD20 (Fig. 268 3). The alterations in the dynamics of B-cells in people receiving aCD20 last for years according to the 269 unpublished results from the NCT00676715 phase-II extension trial 57 , suggesting durable, long-lasting 270 benefits of aCD20 without subsequent dosing 58 . However, this durable effect of aCD20 has shown to be 271 able to alter vaccine immunogenicity for as long as three years, as observed in people with hematological 272 289 While the serum anti-S/S1 assays are deemed predictive of its neutralizing activity 68, 69 , and the serum 290 neutralizing activity predictive of the clinical protection against symptomatic SARS-CoV-2 infection 70 , 291 pwMS with adequate humoral responses -mostly on DMTs other than aCD20 and S1PRM -would 292 theoretically show adequate protection against SARS-CoV-2. However, in the absence of humoral 293 immunization, it is doubted if the T-cells could provide adequate clinical protection among pwMS on 294 aCD20 and S1PRM. The current real-world evidence confirms the predictive effect of seroconversion on 295 post-vaccination COVID-19 incidence and severity 62 , and indicates rising comparative incidence and 296 severity of COVID-19 among pwMS on S1PRM and aCD20 following vaccination of pwMS showed that among the vaccinated pwMS, the ones on aCD20 experienced lower incidence and severity 301 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The present analysis highlight and corroborate the relevance for an optimal treatment strategy in pwMS 308 before COVID-19 vaccination. It was demonstrated that the current vaccination strategy has failed to 309 promote adequate humoral immunity in aCD20-and S1PRM-treated pwMS, which is being translated into 310 low clinical effectiveness of COVID-19 vaccines among them -despite adequate T-cell responses in the 311 ones on aCD20. Their susceptibility to worse COVID-19 outcomes, and the dependency of COVID-19 312 vaccines' humoral immunogenicity to the B-cell dynamics at the time of administration -and therefore, 313 the timing of aCD20 infusion -stress the importance of personalizing vaccination strategies for pwMS on 314 aCD20 with respect to their B-cell profiles and aCD20 infusion timings. Theoretically and based on limited 315 evidence, mode of action and administration method may be important factors to consider also when 316 vaccinating S1PR modulator-treated pwMS, while more evidence is needed to support this claim. Milder 317 humoral and considerable T-cell response blunts -also depending on dosage timings, and higher 318 immunity waning speeds may be present in pwMS on CLAD and ALEM, which subject to confirmation by 319 further evidence, stresses the importance of earlier booster administrations among them. TERI may also 320 cause a humoral immunogenicity blunt, however, being less extensive and clinically-irrelevant based on 321 current evidence; PwMS on TERI may not require countering policies other than being provided with 322 reliable information about the importance of booster doses. Evidence to date does not indicate any 323 significant effect of IFN, GA, DMF, and NTZ on COVID-19 vaccines' immunogenicity and effectiveness. 324 Additionally, as heterologous boosters among healthy people showed to be more immunogenic and We would like to thank Prof. Mohammad Reza Maracy for his valuable methodological consultations. 332 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org/10.1101/2022.02.12.22270883 doi: medRxiv preprint All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org/10.1101/2022.02.12.22270883 doi: medRxiv preprint Abbreviations: ref, reference; vac, vaccination; IFN-g, interferon-gamma; AIM, activation-induced marker; OR, odds ratio; CI, confidence interval; DMT, disease-modifying therapy; UX, unexposed; IFN, interferons; Ni, no information; GA, glatiramer acetate; NE, not estimable; TERI, teriflunomide; S1PRM, sphingosine-1-phosphate receptor modulators; NTZ, natalizumab; CLAD, cladribine; ALEM, alemtuzumab; aCD20, anti-CD20 therapies. 608 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted February 13, 2022. ; https://doi.org/10.1101/2022.02.12.22270883 doi: medRxiv preprint COVID-19 Vaccination with mRNA and Inactivated Virus Vaccines Compared with 577 Homologous Vaccination Strategy against SARS-CoV-2 Variants. Vaccines (Basel) Safety and 580 immunogenicity of heterologous and homologous inactivated and adenoviral COVID-19 vaccines in healthy adults COVID-19 vaccination in patients with 584 multiple sclerosis: what we have learnt by Humoral immune response to 587 COVID-19 mRNA vaccine in patients with multiple sclerosis treated with high-efficacy 588 disease-modifying therapies. Therapeutic advances in neurological disorders Preliminary evidence of blunted 591 humoral response to SARS-CoV-2 mRNA vaccine in multiple sclerosis patients treated 592 with ocrelizumab